The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients.
Robert Charles Newton
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Peggy A Scherle
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Kevin Bowman
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Xiangdong Liu
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Gregory Lawrence Beatty
No relevant relationships to disclose
Peter J O'Dwyer
Research Funding - Incyte
Thomas Gajewski
Consultant or Advisory Role - Incyte; Incyte
Research Funding - Incyte; Incyte
Jill Bowman
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Richard Schaub
Employment or Leadership Position - Incyte
Lance Leopold
Employment or Leadership Position - Incyte
Stock Ownership - Incyte